FRED HUTCHINSON CANCER CENTER

How This Is Building Me podcast, hosted by oncologist D. Ross Camidge, features Mary Redman, a biostatistician and professor, discussing her role in clinical trial design, multidisciplinary collaborations, and nationwide research coordination.

Petros Grivas discusses key bladder cancer trials using immunotherapy, including CheckMate 274, AMBASSADOR, NIAGARA, JAVELIN Bladder 100, CheckMate 901, and EV-302, highlighting their practice-changing impact and adoption in clinical practices.

The Cancer History Project, launched in 2021, aims to preserve oncology's history, exploring milestones like EGFR mutations in lung cancer and the 1964 Surgeon General's Report on Smoking and Health. The project, supported by The Cancer Letter, features multimedia series, podcasts, and institutional histories, attracting growing readership.

The PROSPECT-Lung trial, a large multicenter study, aims to evaluate the role of immunotherapy before and after surgery in resectable non-small cell lung cancer, determining if it improves survival and cancer-free status. It seeks to answer whether perioperative immunotherapy is more effective than adjuvant therapy alone. The trial is part of the NCI's Clinical Trials Innovation Unit, aiming to simplify trials and improve their efficacy.

Herpes simplex 1 and 2, which cause cold sores, remain incurable and can reactivate due to stress. Antiviral medications can manage outbreaks but not eliminate the virus. Researchers are exploring vaccines and gene therapy for prevention and treatment, with some promising early-stage trials.

The Cretostimogene Grenadenorepvec Expanded Access Program (EAP) aims to generate real-world data on the drug's performance in a diverse patient population, offering treatment to those unable to access FDA-approved options. Cretostimogene, an oncolytic immunotherapy for BCG-unresponsive high-risk NMIBC, received FDA Fast Track and Breakthrough Therapy Designations. Topline BOND-003 trial data showed efficacy and tolerability, with a 74.5% overall CR rate. The EAP seeks to recruit diverse sites and collect quality-of-life data, with safety as the primary objective.

Jepson highlights the impact of their endowment funding a pilot study identifying driver mutations in the Pik3ca gene, aiding cancer treatment development. Since 2005, donations have totaled nearly $250,000, accelerating research and funding nine breast cancer pilot studies.

Terry Pirovolakis developed a gene therapy for his son's ultra-rare disease SPG50 and founded Elpida Therapeutics to help other families. AbbVie's tavapadon showed success in another Parkinson's Phase 3 trial. The BIOSECURE Act, aimed at preventing U.S. biopharma companies from working with Chinese 'companies of concern,' was excluded from the defense budget bill. President-elect Trump echoed Robert F. Kennedy Jr.'s vaccine skepticism. A study highlighted disparities in bone marrow transplant access based on socioeconomic status.

Arcellx presents positive Phase 2 iMMagine-1 study data for anito-cel in relapsed or refractory multiple myeloma at ASH, showing 97% ORR and 62% CR/sCR. No delayed neurotoxicities observed; 30.2-month median PFS in Phase 1 study. Additional ASH presentations and a webcast event scheduled.

Arcellx announces 97% overall response rate and 62% complete response rate in Phase 2 iMMagine-1 study of anitocabtagene autoleucel for relapsed or refractory multiple myeloma, with 93.1% MRD negativity and no delayed neurotoxicities observed.